To enhance the diagnosis and treatment of complex tumor cases, Cancer Center of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) has recently invited two internationally renowned experts in the field of breast cancer to carry out international consultations on challenging cases and to conduct a series of academic exchange activities.
On November 20, Professor Dejan Juric, Director of the Termeer Center for Targeted Therapies at Massachusetts General Hospital, USA, was invited to visit the FAH. As a member of the American Society of Clinical Oncology and an editorial board member of Clinical Cancer Research, he has published 385 papers with 12,652 citations and serves as lead principal investigator for five projects. Professor He Jianjun, discipline leader of Breast Surgery at the FAH, and Yang Jin, Director of the Cancer Center, co-chaired the meeting, delivered welcome remarks, and presented him with an honorary certificate as an international remote consultation expert for complex cases.
In the academic session, Professor Dejan Juric provided a systematic overview of the evolving treatment paradigm for HR+/HER2- breast cancer. Drawing on the MONALEESA series of studies, he gave an in-depth explanation of the breakthrough advances and multiple mechanisms of action of CDK4/6 inhibitors, and proposed a new diagnostic and therapeutic paradigm of “early intensified intervention to eradicate micrometastatic lesion”. Zhang Huimin, Associate Director of the Department of Breast Surgery presented the department’s strengths in technical innovations such as breast-conserving surgery and minimally invasive procedures, as well as in tumor microenvironment research and clinical trials. Dr. Gao Huan from the Phase I Clinical Trial Center reported on the center’s development. During the case discussion, focusing on a young patient with metastatic breast cancer who had developed resistance to CDK4/6 inhibitors, Professor Juric recommended completing genomic testing and switching to ADC therapy, providing crucial guidance for clinical practice. In addition, he also shared mature experience from Massachusetts General Hospital in areas such as tiered MDT decision-making and monitoring of key nodes along the diagnostic and treatment pathway.
On November 12, Sibylle Loibl, Professor of Obstetrics and Gynecology at Goethe University Frankfurt and Chairman of the German Breast Group (GBG), was invited for academic exchanges. She has dedicated profound expertise to the fields of neoadjuvant therapy for breast cancer and breast cancer in young women, with over 500 academic publications and leadership in multiple transformative clinical trials. The meeting was chaired by Professor Yang Jin, who delivered the welcome address and presented her with an honorary certificate.
Professor Sibylle Loibl presented the clinical research progress of the GBG and delivered an academic lecture titled “Precision Treatment of Triple-Negative Breast Cancer in the ADC Era”, in which she analyzed the clinical challenges of TNBC and highlighted key breakthroughs with Trop-2-targeted ADCs such as sacituzumab govitecan (SG). Dr. Gao Huan reported on the development of Cancer Center and the Phase I Clinical Trial Center, as well as the operation of 33 record-filed MDTs and 14 routinely running tumor MDTs. During the case discussion, for a very young TNBC patient who was HRD-positive and chemotherapy-resistant, Professor Loibl recommended timely adjustment of the SG treatment regimen based on liquid biopsy results, providing new ideas for subsequent diagnosis and treatment.
